dpp-4 inhibitor and glp-1 receptor agonist combination not recommended ada Type 2 Diabetes Guidelines From The 2017 Guidelines - Page 5 of 9 Insights into the Roles of

It can be prescribed off-label to promote weight loss in some cases

Exenatide has demonstrated the ability to headache frequency [19], however its role in headache in raised ICP is yet to be fully determined headaches severity were similar in both trial arms [19]

centrally-mediated loss of appetite & increased thermogenic activity GLP-1 receptors are found in regions of the hindbrain and hypothalamus that regulate feeding behavior Centrally mediated GLP-1 effects include: reduction of food intake - resulting in weight loss due to reduced caloric intake activation of sympathetic pathways in the dorsomedial hypothalamus (DMH) and ventromedial nucleus of the hypothalamus (VMH) that increase neuronally mediated thermogenic activity of brown adipose tissue (BAT) resulting in increased energy expenditure with associated weight loss (Contreras et al, 2017

Given these challenges, most existing pediatric data are derived from retrospective studies rather than controlled prospective trials

Phase 3 studies using mazdutide as obesity treatment in a Chinese population (doses between 4 and 9 mg) are also ongoing (NCT05607680, NCT06164873)